ALG Lung Cancer Registry (SAFRO2202)
Observational Study of the Epidemiological, Clinical, and Diagnostic Profile, Treatment Patterns, and Outcomes of Lung Cancer.
This registry will collect medical information from adults in Algeria who have been diagnosed with any type of lung cancer to see patterns in diagnosis, treatment, and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3750 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Société Algérienne de Formation et de Recherche en Oncologie Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 21 sites (Algiers, Algiers Province and 20 other locations) |
| Trial ID | NCT07161882 on ClinicalTrials.gov |
What this trial studies
SAFRO2202 is a prospective, multicenter, non-interventional registry enrolling adults with confirmed lung cancer (NSCLC, SCLC, or carcinoid) who were diagnosed at inclusion or within the prior 12 months. The study runs across 21 public and university hospitals in Algeria and captures data during routine clinical care with no study-specific visits or interventions. Patient data are entered into a secure electronic case report form and include demographics, risk factors (notably smoking), tumor histology, staging, molecular markers (for example EGFR, ALK, PD-L1, KRAS, ROS1), treatments, and outcomes including treatment-related side effects. The registry plans to enroll about 1,500 patients per year over a 30-month period to generate real-world national-level evidence on lung cancer management and outcomes.
Who should consider this trial
Good fit: Adults aged 18 or older with a histologically confirmed diagnosis of NSCLC, SCLC, or carcinoid tumor diagnosed at inclusion or within the past 12 months who are fully managed at one of the participating oncology or pulmonology departments and who provide informed consent.
Not a fit: Patients under 18, those diagnosed more than 12 months before inclusion, those not managed at a participating center, or those currently enrolled in an interventional clinical trial are not eligible and therefore will not benefit from participation in this registry.
Why it matters
Potential benefit: If successful, the registry could improve understanding of how lung cancer is diagnosed and treated across Algeria and guide better resource planning and treatment choices for future patients.
How similar studies have performed: National and regional lung cancer registries have previously provided valuable real-world insights into epidemiology and treatment patterns, though they do not test new therapies directly.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor) * Diagnosed at the time of inclusion or within the 12 previous months * Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public/university hospitals * Signed informed consent obtained Exclusion Criteria: * Prior enrollment in this study * Participation in an interventional clinical trial
Where this trial is running
Algiers, Algiers Province and 20 other locations
- Centre Pierre et Marie Curie — Algiers, Algiers Province, Algeria (Recruiting)
- Chu Beni Messous - Isaad Hassani — Algiers, Algiers Province, Algeria (Recruiting)
- CHU Mohamed Lamine Debaghine - Bab-el-Oued — Algiers, Algiers Province, Algeria (Recruiting)
- Chu-Beni Messous - Isaad Hassani — Algiers, Algiers Province, Algeria (Recruiting)
- EPH Rouiba — Algiers, Algiers Province, Algeria (Recruiting)
- CLCC Annaba — Annaba, Annaba, Algeria (Recruiting)
- CLCC Batna — Batna City, Batna, Algeria (Recruiting)
- CAC-CHU Frantz Fanon — Blida, Blida Province, Algeria (Recruiting)
- CHU- Hôpital Khelil Amrane — Béjaïa, Béjaia Province, Algeria (Recruiting)
- CHU Dr Abdesselam Benbadis — Constantine, Constantine Province, Algeria (Recruiting)
- EH Didouche Mourad — Constantine, Constantine Province, Algeria (Recruiting)
- CLCC Draâ Ben Khedda — Tizi Ouzou, Draâ Ben Khedda, Algeria (Recruiting)
- CAC-Laghouat — Laghouat, Laghouat Province, Algeria (Recruiting)
- CAC Oran EL HASSI- EMIR ABDELKADER — Oran, Oran Province, Algeria (Recruiting)
- CHU Dr. Benaouda Benzerdjeb — Oran, Oran Province, Algeria (Recruiting)
- EHS 1er novembre — Oran, Oran Province, Algeria (Recruiting)
- CAC- Ouargla — Ouargla, Ouargla Province, Algeria (Recruiting)
- CAC El OUED — El Oued, Oued Souf, Algeria (Recruiting)
- CAC- Sidi Bel Abbès — Sidi Bel Abbes, Sidi Bel Abbès Province, Algeria (Recruiting)
- EPH- Sidi Ghiles — Tipasa, Sidi Ghiles, Algeria (Recruiting)
- CAC-Sétif — Sétif, Sétif Province, Algeria (Recruiting)
Study contacts
- Principal investigator: Adda BOUNEDJAR, Professor of Medical Oncology — Frantz Fanon University Hospital, Cancer Center (CAC), Blida, Algeria
- Study coordinator: Louisa ISSIAKHEM LOUNICI, CEO
- Email: l.issiakhem@cmsolutionsdz.com
- Phone: +213 770 48 43 36
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.